- Home
- HSCS vs QLGN Comparison
HSCS vs QLGN Comparison
Compare HSCS & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- QLGN
- Stock Information
- Founded
- HSCS 2007
- QLGN 1996
- Country
- HSCS United States
- QLGN United States
- Employees
- HSCS N/A
- QLGN N/A
- Industry
- HSCS Medical Specialities
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- HSCS Health Care
- QLGN Health Care
- Exchange
- HSCS Nasdaq
- QLGN Nasdaq
- Market Cap
- HSCS 2.7M
- QLGN 2.7M
- IPO Year
- HSCS 2022
- QLGN N/A
- Fundamental
- Price
- HSCS $2.67
- QLGN $4.83
- Analyst Decision
- HSCS Strong Buy
- QLGN
- Analyst Count
- HSCS 1
- QLGN 0
- Target Price
- HSCS $15.00
- QLGN N/A
- AVG Volume (30 Days)
- HSCS 26.2K
- QLGN 99.6K
- Earning Date
- HSCS 12-12-2024
- QLGN 11-14-2024
- Dividend Yield
- HSCS N/A
- QLGN N/A
- EPS Growth
- HSCS N/A
- QLGN N/A
- EPS
- HSCS N/A
- QLGN N/A
- Revenue
- HSCS $18,600.00
- QLGN N/A
- Revenue This Year
- HSCS $8,948.39
- QLGN N/A
- Revenue Next Year
- HSCS $27.27
- QLGN N/A
- P/E Ratio
- HSCS N/A
- QLGN N/A
- Revenue Growth
- HSCS 853.85
- QLGN N/A
- 52 Week Low
- HSCS $2.36
- QLGN $3.34
- 52 Week High
- HSCS $29.00
- QLGN $39.15
- Technical
- Relative Strength Index (RSI)
- HSCS 40.14
- QLGN 45.01
- Support Level
- HSCS $2.53
- QLGN $3.34
- Resistance Level
- HSCS $2.76
- QLGN $4.56
- Average True Range (ATR)
- HSCS 0.17
- QLGN 0.58
- MACD
- HSCS 0.02
- QLGN 0.15
- Stochastic Oscillator
- HSCS 22.83
- QLGN 82.69
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.